Study objective: The optimal intranasal volume of administration for achieving timely and effective sedation in children is unclear. We aimed to compare clinical outcomes relevant to procedural sedation associated with using escalating volumes of administration to administer intranasal midazolam.
INTRODUCTION Background
The intranasal route is an effective means of administering sedatives to children who require procedural sedation.
1-3 Intranasal administration delivers the sedative to the highly vascularized nasal mucosa and the olfactory tissue that is in direct contact with the central nervous system (termed the "nose-brain pathway"), thereby bypassing firstpass metabolism.
1, 4 Although there are commercial products designed specifically for intranasal drug delivery, it is common practice in emergency departments (EDs) to use parenteral formulations of sedatives for intranasal administration.
1-3,5-7 However, commonly available concentrations of these sedatives often necessitate large total volumes to deliver the required weight-based dose in children. In the clinical setting, this total volume is often divided into smaller aliquots, or volumes of administration, that are administered repeatedly by alternating between both nostrils until the total volume is delivered.
Importance
Although the volume of administration is a fundamental aspect of intranasal administration, it is unclear what volume is optimal for achieving timely and effective sedation when intranasal sedatives, such as midazolam, are administered to children. Intranasal medications are typically administered with a mucosal atomization device, with a commonly recommended optimal volume of administration of approximately 0.3 mL and
Editor's Capsule Summary
What is already known on this topic The intranasal route is an effective way to provide sedative medication to children.
What question this study addressed
What is the optimal volume to administer aliquots of intranasal midazolam?
What this study adds to our knowledge In this 3-arm randomized controlled trial in 96 children receiving 0.2-, 0.5-, or 1-mL aliquots, time to onset and adequacy of sedation were clinically similar among groups. Clinicians least preferred the 0.2-mL volume because administration was more challenging.
How this is relevant to clinical practice
This study suggests that each volume may have pros and cons and that optimal volume may vary among patients and clinicians.
a maximum of 1 mL. 1, 8 This is in contrast to other recommendations stating that a volume of administration should not exceed 0.15 or 0.2 mL because of concerns that any volume in excess of these limits will become runoff, drain out of the nose and not be absorbed, or will be swallowed and subject to first-pass metabolism. 4, [9] [10] [11] [12] [13] [14] [15] 
Goals of This Investigation
The aim of this study was to determine the optimal volume of administration of intranasal midazolam in children by comparing clinical outcomes relevant to procedural sedation associated with escalating volumes of administration (0.2, 0.5, and 1 mL) during laceration repair in an ED. Our primary outcome was time to onset of minimal sedation. Our secondary outcomes included procedural distress, time to procedure start, deepest level of sedation achieved, adverse events, and clinician and caregiver satisfaction. We hypothesized that using a volume of administration of 0.2 mL would be associated with a shorter time to onset of minimal sedation compared with using a volume of administration of either 0.5 or 1 mL because we expected that a volume of administration of 0.2 mL would have the least amount of runoff compared with larger volumes. 4, [9] [10] [11] [12] [13] [14] [15] 
MATERIALS AND METHODS Study Design
We conducted a randomized, outcome assessor-blinded, 3-arm parallel group (1:1:1), superiority clinical trial in a single urban pediatric ED with an annual census of approximately 55,000 children per year. Our institutional review board approved this study, and written informed consent was obtained from each participant's legal guardian.
Selection of Participants
Between November 2013 and September 2015, we enrolled a convenience sample of children aged 1 to 7 years who presented to the ED with a simple laceration (defined as length <5 cm and not requiring wound revision) and whose attending physician determined that intranasal midazolam was indicated to facilitate the repair. Patients were enrolled when a research coordinator or study physician was available (9 AM to 10 PM on weekdays; variable on overnights and weekends). We excluded children for any of the following: a history of developmental delay, underlying neurologic abnormality, or autism; illness associated with chronic pain; known allergy to midazolam or any other benzodiazepine; weight less than 10 kg; eyelid lacerations (ie, repair would necessitate closed eyes); nasal obstruction that could not be easily cleared; did not speak English or Spanish; or was a foster child or ward of the state.
Interventions
We used an online randomization program, which maintained allocation concealment, to randomize children in blocks of 3 to receive the total dose of midazolam, using 1 of 3 volumes of administration: 0.2, 0.5, and 1 mL. These volumes were selected according to previous recommendations regarding optimal volume of administration, clinical feasibility, and current clinical practice. 1, 4, [8] [9] [10] [11] [12] [13] [14] [15] Clinicians applied lidocaine-epinephrinetetracaine gel to all lacerations in a standardized fashion, unless contraindicated. Lidocaine injection for local anesthesia was administered at the discretion of the clinician performing the laceration repair (ie, the "proceduralist"). All children received an integrative (nonpharmacologic) intervention, such as a child life specialist, or a developmentally appropriate form of active or passive distraction.
All children received midazolam at 0.5 mg/kg (concentration 5 mg/mL), with a maximum total dose of 10 mg (maximum volume of 2 mL). The medication was administered in aliquots based on the assigned volume of administration by an attending pediatric emergency physician using an LMA MAD Nasal (Teleflex, Morrisville, NC) device attached to a 1-mL syringe with 0.01-mL scale markings. 8 Before every administration, the attending physician completed an "intranasal administration refresher" with a member of the study team ( Figure E1 , available online at http://www.annemergmed.com). During the refresher, the attending physician was required to demonstrate that he or she could administer the assigned volume of administration accurately. We made the refresher mandatory to ensure that the administration was consistently performed in a standardized fashion and that the assigned volume of administration would be administered correctly. We administered the intranasal midazolam first into one nostril, using the assigned volume of administration, and then alternated between nostrils until the total volume was delivered. Because the total volume required by each patient was not always divisible by the assigned volume of administration into an equal number of administrations, we administered as many aliquots as possible with the assigned volume of administration and then administered the remaining volume last. Medication could be delivered into the second nostril immediately after the first, but we waited a period of 10 seconds before readministering the medication to the same nostril. We chose the interval of 10 seconds in accordance with both expert consultation with otolaryngologists and pharmacologists and feasibility in a clinical setting. For example, a total dose of 8 mg (and therefore a total volume of 1.6 mL when using the 5-mg/mL concentration of midazolam) would be required for a 16-kg child. If the child were assigned to receive intranasal midazolam with a volume of administration of 0.5 mL, 0.5 mL would be administered to the first nostril, and then another 0.5 mL would be immediately administered to the second nostril. Ten seconds later, another 0.5 mL would be administered to the first nostril, with the remaining 0.1 mL immediately administered to the second nostril, thereby completing administration of the total volume.
It was at the discretion of the proceduralist, who was not blinded, when to begin the procedure; whether restraining the child during the procedure was indicated (and how restraint was implemented); and whether to abort a procedure due to perceived inadequate sedation.
Methods of Measurement and Outcome Measures
A member of the study team videotaped patients for a 1-minute period before intranasal midazolam administration (the baseline period) and then through the entirety of the procedure, starting from just before administration of the intranasal midazolam until 1 minute after procedure completion, defined as time the last suture was cut. Steps were taken during the videotaping and video scoring to create a standardized 1-minute blinding period, starting from the time that the first aliquot was administered, in order to blind outcome assessors to both visual and auditory cues during the administration of the intranasal midazolam.
Three of 4 trained physician outcome assessors (D.S.T., M.I., D.B.F., and J.B.) independently scored each video recording, blinded to the assigned volume of administration and to the results of the other assessors. If one of them was involved in any way with an enrollment, he or she was not eligible to evaluate that video recording. Outcome assessors scored the video recordings in a randomized order that was unique to each of the assessors.
Each outcome assessor evaluated the primary outcome, time to onset of minimal sedation, as defined by the University of Michigan Sedation Scale, which is a 5-point (0 to 4) scale that has been validated and used for children to identify different depths of sedation, where 0¼awake and alert, 1¼minimally sedated (tired/sleepy, appropriate response to verbal conversation or sound), 2¼moderately sedated, 3¼deeply sedated, and 4¼unarousable. 16 The primary outcome was evaluated by measuring the time starting from the administration of the first aliquot of intranasal midazolam until the onset of minimal sedation.
The outcome assessors evaluated procedural distress, a secondary outcome, with the Observational Scale of Behavioral Distress-Revised. 17 The scale was used to score 4 predetermined clinically relevant phases: baseline, irrigation or cleaning, laceration repair, and postprocedure. The scale is an 8-factor, weighted observational scale used to measure distress associated with medical procedures, which has been validated in children and adults aged 1 to 20 years. 5, [18] [19] [20] [21] [22] The total Observational Scale of Behavioral Distress-Revised score is the sum of the scale scores for each phase, with each phase assigned a score from 0 to 23.5 (0¼no distress, 23.5¼maximum distress), based on the frequency and types of behaviors observed during a predetermined number of 15-second intervals during each phase. The scale was used to identify statistically significant differences between groups because the change in score representing a clinically meaningful difference and the range of scores representing categories of pain intensity (ie, mild, moderate, and severe)
have not yet been clearly defined. Each outcome assessor also determined time to procedure start and deepest level of sedation achieved (as per the University of Michigan Sedation Scale) when scoring the video recording.
The study team member documented the presence of any adverse events during the procedure, including vomiting, apnea (no breath for >20 seconds), paradoxic reaction (ie, agitation precipitated by midazolam), and the need for supplemental oxygen, airway repositioning, or bag-valve-mask ventilation. We also documented whether, per the proceduralist, there was inadequate sedation during the laceration repair, resulting in the inability to complete the procedure. Children who did not reach adequate sedation by 20 minutes after intranasal administration, as per the proceduralist, were also considered to have had inadequate sedation.
After completion of the procedure, a study team member evaluated clinician and caregiver satisfaction by interviewing the attending physician who administered the intranasal midazolam, the proceduralist who performed the laceration repair, and the child's caregiver. Clinicians and caregivers used a 5-point Likert scale ("strongly agree," "agree," "neither agree nor disagree," "disagree," or "strongly disagree") to answer questions related to their satisfaction with ease of intranasal administration, child comfort during intranasal administration, and the adequacy of sedation achieved.
Primary Data Analysis
For our primary outcome of time to onset of minimal sedation, we compared the 3 groups with the KruskalWallis test, with follow-up pairwise comparisons between groups with the Wilcoxon rank-sum test. We chose to use a rank test so that patients who did not have a time to onset of minimal sedation documented (eg, if they not achieve adequate sedation by 20 minutes or if the procedure was started before onset of minimal sedation) could still be included in the analysis. These patients were assigned a maximal score (eg, 999 minutes) in place of a time to onset of minimal sedation to represent a maximal time for the primary outcome, thereby using the most conservative assumption possible. The median of the 3 raters' scores was used as the time to onset of minimal sedation for each patient, and the median time to onset of minimal sedation for each group was determined and compared. We considered a statistically significant difference for the primary outcome at an experimentwise a¼.05. For followup pairwise comparisons, we used a Bonferroni adjustment for 3 comparisons, 2-tailed per comparison (a¼.0167). We determined our sample size by designing the study to have 0.80 power to detect a clinically meaningful difference in time to onset of minimal sedation of 1.5 minutes, with an estimated SD of 2 minutes for each group. 7, 23 The goal sample size was 108, but enrollment was stopped early because of constraints related to funding.
We analyzed continuous secondary outcomes (ie, Observational Scale of Behavioral Distress-Revised, time to procedure start) with the 1-way ANOVA test, and ordinal and nominal outcomes (ie, deepest level of sedation, adverse events, and satisfaction) with the c 2 test. 24 An interclass correlation coefficient calculation was performed on the primary outcome of time to onset of minimal sedation and the secondary outcome of procedural distress (Observational Scale of Behavioral Distress-Revised). The Shrout-Fleiss interclass correlation coefficient (1,k) statistic was calculated to show the correlation of raters when each subject was rated by multiple raters, with raters assumed to be randomly assigned to subjects and all subjects have the same number of raters. 25 Statistical analyses were performed with SPSS (version 22; IBM Corporation, Armonk, NY) and SAS (version 9.4; SAS Institute, Inc., Cary, NC).
RESULTS
We enrolled 99 patients: 96 were evaluated for the primary outcome and secondary outcomes of time to onset of procedure, deepest level of sedation, adverse events, and satisfaction; 90 patients were analyzed for procedural distress (Figure) . The patient, laceration, and procedural characteristics were similar across all 3 groups, except there were more male patients in the 0.5-mL group and fewer children who had a history of any painful or distressing medical procedure in the 0.2-mL group (Tables 1 and 2 ). All patients received the intervention to which they were allocated.
The median times to onset of minimal sedation when a volume of administration of 0.2, 0.5, and 1 mL was used were 4.7 minutes (95% confidence interval [CI] 3.8 to 5.4 minutes), 4.3 minutes (95% CI 3.9 to 4.9 minutes), and 5.2 minutes (95% CI 4.6 to 7 minutes), respectively (Table 3) . Overall, the difference between groups was statistically significant (P¼.048). When follow-up comparisons were conducted between groups, while adjusting for multiple comparisons with the Bonferroni correction (a¼.0167), a shorter time to onset of minimal sedation (0.9 minutes) was observed when a volume of administration of 0.5 mL was used compared to when a volume of administration of 1 mL was used (P¼.01). However, this difference in time to onset was not clinically meaningful, according to the a priori threshold of 1.5 minutes. There were no statistically or clinically meaningful differences identified when the remaining groups were compared with each other. There were also no significant differences between any of the groups in regard to procedural distress, time to procedure start, and deepest level of sedation (Table 3 ). There were no paradoxic reactions and no serious adverse events. The only adverse events observed were vomiting and inadequate sedation, with no difference between the 3 groups (Table 4) . Table 5 presents clinician and caregiver satisfaction. Fewer clinicians agreed or strongly agreed that they were satisfied with ease of administration when using a volume of administration of 0.2 mL compared with the other groups. The Shrout-Fleiss interclass correlation coefficient (1,k) statistic was 0.59 for the time to onset of minimal sedation (moderate agreement) and 0.92 for procedural distress, ie, Observational Scale of Behavioral Distress-Revised (almost perfect agreement).
LIMITATIONS
Our study has several limitations. First, the inherent subjective nature of some outcomes (ie, time to onset of minimal sedation, procedural distress, depth of sedation, and adequacy of sedation) may have potential for bias, although we attempted to minimize it by having 3 separate blinded evaluators. Second, some of our secondary outcomes (eg, time to procedure start, inadequate sedation) were determined by nonblinded participants (ie, proceduralist). If the proceduralists believed that smaller volumes of administration were associated with less runoff and therefore better absorption, that could have resulted in a trend toward shorter times to procedure start and fewer patients with inadequate sedation in the smaller compared with larger volume of administration groups. Third, we did not standardize the decision to implement restraint on children during laceration repairs and could not standardize when or how restraint was administered by each proceduralist. Differential use of aggressive restraint not only might contribute to a higher Observational Scale of Behavioral Distress-Revised score but also potentially precipitate or exacerbate distress in a child. Fourth, we did not achieve our desired sample size by 9 subjects (3 per group). It is possible that if we had enrolled the remaining 9 subjects, there would have been an effect size larger than that observed, or that the precision of our estimates would have improved so that a statistical difference became apparent between other groups. However, even if either of these scenarios had occurred, it is unlikely that an increase in sample size of 10% would have resulted in an effect size 50% larger than that observed and therefore unlikely that a clinically meaningful difference would have become apparent.
DISCUSSION
The findings of our study demonstrate the clinical outcomes associated with using escalating volumes of administration to deliver midazolam by the intranasal route to children undergoing laceration repairs. Although a volume of administration of 0.5 mL was associated with a statistically shorter time to onset of minimal sedation compared with a volume of administration of 1 mL (4.3 and 5.2 minutes, respectively), a clinically meaningful difference (defined a priori as 1.5 minutes) was not observed between these 2 groups, nor when comparing any of the groups with one another. Similarly, there was no difference in time to procedure start, which would be consistent with the absence of a clinically meaningful difference in time to onset of minimal sedation. There was also no difference when comparing procedural distress and deepest level of sedation achieved, suggesting that using any of the 3 volumes of administration will produce clinically comparable outcomes.
Our findings corroborate one aspect of existing guidelines about the volume of administration that should be used when administering intranasal medications. Our study supports the recommendation that it is acceptable to administer up to a 1-mL volume. 1, 8 This is in light of concerns about runoff caused by using a larger volume of administration that might lead to suboptimal efficacy; our data demonstrate that the largest volume of administration is still associated with clinical outcomes comparable to using a smaller volume of administration. Our results suggest that it would be acceptable to administer intranasal midazolam with a volume of administration of 0.5 mL until a desired total volume is delivered, or to divide total volumes into 2 separate volumes of administration (so that each nostril receives 1 aliquot and the surface area available for absorption is effectively doubled by using both nostrils), as long as the maximum volume of administration of each aliquot is less than or equal to 1 mL.
It does not appear that using a volume of administration as small as 0.2 or 0.3 mL is associated with any measurable advantage in clinical outcomes relevant to procedural sedation compared with using a volume of administration as large as 0.5 or 1 mL. One explanation for this lack of difference between groups could be that some of the runoff associated with using a higher volume of administration of midazolam may have been swallowed and absorbed orally, contributing to the clinical outcomes observed. However, the times to onset of minimal sedation we observed (Table 3) occurred much sooner than midazolam would be expected to take effect when absorbed orally, and most of the procedures were completed before or during the expected time of onset of minimal sedation for oral midazolam (Table 1) . 6, [26] [27] [28] Another explanation for this lack of difference between groups may be that the volume of administration may not be as consequential a factor in the absorption of intranasal medications compared with other variables such as drug concentration (which remained constant) and the total volume administered. Despite our measures taken to facilitate absorption in a clinically feasible manner when multiple aliquots were required (ie, the 10-second pause), it is possible that absorption of the administered aliquot during each pause was not complete. As a result, the amount of UMSS, University of Michigan Sedation Scale. *Total OSBD-R score ranged from 0 to 94: 0¼no distress, 94¼maximum distress. † n¼30, 29, and 31 for 0.2-, 0.5-, and 1-mL VOA, respectively. ‡ OSBD-R score range for each phase from 0 to 23.5; 0¼no distress, 23.5¼maximum distress. § UMSS score from 0 to 4: 0¼awake and alert; 1¼minimal sedation; 2¼moderate sedation; 3¼deep sedation; 4¼unarousable. runoff experienced, and therefore the total volume of medication retained, may have remained similar between the 3 groups despite our varying the volume of administration. Fewer clinicians were satisfied with ease of administration when using the smallest volume of administration of 0.2 mL. This likely reflects the need to administer a larger number of aliquots to completely deliver a given total volume of midazolam when using a small volume of administration, such as 0.2 or 0.3 mL. For example, using a volume of administration of 0.2 mL would necessitate that as many as 10 separate aliquots be administered (depending on the dose required, with a maximum dose of 10 mg) to deliver the total volume, whereas using a volume of administration of 1 mL would require as few as 1 to 2 aliquots. The larger number of aliquots associated with using a smaller volume of administration is likely to be more poorly tolerated by young children, with the problem further exacerbated by the burning sensation associated with each aliquot of midazolam. Because there is likely poorer patient acceptance without any clear clinical benefit to using a small volume of administration that requires a larger number of aliquots, using a larger volume of administration is likely preferable by clinicians because only a smaller number of aliquots would be required, and the medication could be administered over a shorter period of time.
However, our findings do not discount the potential value of using a smaller volume of administration in specific circumstances. For instance, minimizing the volume of administration may be more applicable when using medication formulations of higher concentrations, which would allow the total dose required to be administered in a single aliquot. [29] [30] [31] [32] [33] [34] Under these conditions, runoff would potentially reduce medication effectiveness because the patient would receive an inadequate dose. However, these concentrated formulations are not readily available. Most of the medications that are administered by the intranasal route in children are most commonly available in concentrations that necessitate that large volumes be divided into smaller aliquots because of weight-based dose requirements. 3, 6, 35, 36 Further study is necessary to evaluate whether our findings are generalizable to other intranasal medications in children. Nasal and olfactory absorption is governed by a number of factors, one of them being the physicochemical properties of a drug. With all other factors remaining similar, we expect that medications with physicochemical properties similar to those of midazolam would produce comparable effects when administered using the different volumes of administration described in our study. Fentanyl, for example, may demonstrate comparable clinical efficacy when administered intranasally with escalating volumes of administration, given that it has a molecular weight and lipophilicity comparable to that of midazolam, and a pH that is similarly favorable for intranasal absorption. [37] [38] [39] [40] There was a statistically but not clinically meaningful shorter time to onset of minimal sedation when using a volume of administration of 0.5 mL compared with 1 mL for administration of intranasal midazolam to children undergoing laceration repair. A volume of administration of 0.2, 0.5, or 1 mL produced comparable and acceptable outcomes relevant to procedural sedation in children. Fewer clinicians were satisfied with ease of administration of intranasal midazolam when using a volume of administration of 0.2 mL.
